Business Context and Reporting Period
Company: MRI Interventions, Inc. (Note: Metadata lists "Clearpoint Neuro, Inc." but the filing text identifies the registrant as MRI Interventions, Inc.)
Filing Type: Form 8-K (Current Report)
Date: March 22, 2016
Event: Entry into a Material Definitive Agreement to restructure a subordinated secured note with Brainlab AG.
Key Financial Metrics and Transaction Details
This filing details a debt restructuring rather than standard operating financial results. Key transaction figures include:
- Old Note Principal: $4,289,444 (maturing April 5, 2016).
- Accrued Interest Paid: $739,323.46 (paid immediately to Brainlab).
- Principal Cancellation via License: $1,000,000 (in exchange for a patent and technology license).
- Principal Cancellation via Equity: $1,289,444.44 (in exchange for 3,972,410 units of stock and warrants).
- New Note Principal: $2,000,000 (restructured debt).
- New Note Terms: 5.5% interest, payable quarterly in arrears, maturing December 31, 2018.
- Equity Issuance: 3,972,410 units consisting of common stock, Series A Warrants (exercise price $0.4058), and Series B Warrants (exercise price $0.5275).
Material Changes Versus Prior Period
The filing does not provide comparative period financial statements (revenue, profit, or cash flow). The material change is the conversion of a significant portion of the company's debt obligation into equity and a technology license, extending the maturity of the remaining debt from April 2016 to December 2018.
Guidance, Outlook, Risks, and Contingencies
- Closing Conditions: The transaction is subject to customary closing conditions, with an anticipated closing date on or before April 4, 2016.
- Registration Rights: The company must file a registration statement within 60 days of closing. Failure to file by the deadline or have it declared effective by the 75th/120th day will result in liquidated damages to Brainlab.
- Technology License: Brainlab will develop proprietary software for the SmartFrame device; the company retains the right to independently develop its own software.
- Risks: Forward-looking statements warn that the transaction may not close on the described terms or in a timely manner. General risk factors are referenced in the 2015 Form 10-K and 2015 Form 10-Q.
Important Facts for Investor Verification
- Verify the final closing date of the transaction (anticipated April 4, 2016).
- Confirm the filing and effectiveness of the Registration Statement required under the Registration Rights Agreement to avoid liquidated damages.
- Review the specific terms of the Patent and Technology License Agreement (Exhibit 10.3) to understand the scope of Brainlab's software development rights.
- Monitor the dilution impact of the 3,972,410 units issued and the potential exercise of Series A and Series B warrants.
- Check subsequent filings for the actual payment of the $739,323.46 interest obligation.